Kymera Therapeutics (NASDAQ:KYMR) COO Jeremy Chadwick Sells 5,251 Shares

17 Apr 2026, 06:00 by Amy Steele · The Cerbat Gem

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) COO Jeremy Chadwick sold 5,251 shares of the stock in a transaction on Tuesday, April 14th. The shares were sold at an average price of $90.00, for a total transaction of $472,590.00. Following the sale, the chief operating officer directly owned 61,202 shares of the company’s stock, valued at $5,508,180. The trade was a 7.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Kymera Therapeutics Trading Down 3.2%

KYMR stock opened at $86.14 on Friday. The stock has a market capitalization of $7.03 billion, a price-to-earnings ratio of -23.41 and a beta of 2.28. The firm’s 50-day moving average price is $83.89 and its two-hundred day moving average price is $74.23. Kymera Therapeutics, Inc. has a 12-month low of $24.72 and a 12-month high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) last posted its earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The firm had revenue of $2.87 million for the quarter, compared to analysts’ expectations of $14.80 million. During the same quarter in the prior year, the company posted ($0.88) earnings per share. The business’s revenue for the quarter was down 60.8% on a year-over-year basis. Equities analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. US Bancorp DE boosted its position in shares of Kymera Therapeutics by 9.8% during the third quarter. US Bancorp DE now owns 1,865 shares of the company’s stock valued at $106,000 after purchasing an additional 166 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Kymera Therapeutics by 9.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,764 shares of the company’s stock worth $156,000 after purchasing an additional 248 shares in the last quarter. Larson Financial Group LLC raised its holdings in Kymera Therapeutics by 36.9% in the fourth quarter. Larson Financial Group LLC now owns 1,064 shares of the company’s stock worth $83,000 after purchasing an additional 287 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its position in Kymera Therapeutics by 3.3% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 12,655 shares of the company’s stock valued at $985,000 after buying an additional 410 shares during the period. Finally, Smartleaf Asset Management LLC boosted its holdings in shares of Kymera Therapeutics by 382.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after buying an additional 424 shares in the last quarter.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Royal Bank Of Canada reissued an “outperform” rating and set a $108.00 target price on shares of Kymera Therapeutics in a research note on Thursday, February 26th. Wall Street Zen lowered Kymera Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Piper Sandler lifted their price target on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the company an “overweight” rating in a report on Thursday, February 26th. B. Riley Financial boosted their price objective on shares of Kymera Therapeutics from $80.00 to $117.00 and gave the company a “buy” rating in a research report on Monday, December 22nd. Finally, BTIG Research decreased their price objective on shares of Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating for the company in a report on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Kymera Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $118.90.

Get Our Latest Research Report on KYMR

Key Stories Impacting Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

Neutral Sentiment: Director Bruce Booth executed multiple small sales over April 14–15 under a pre-arranged Rule 10b5-1 plan (3,135 @ ~$90.10; 2,200 @ ~$89.95; 4,159 @ ~$89.97). Because these were part of a 10b5-1 plan, they are largely viewed as planned/liquidity-driven rather than a signal of private negative information. SEC Form 4
Negative Sentiment: COO Jeremy G. Chadwick sold 6,551 shares across April 14–15 (~$90 avg), representing roughly a 7.9% then 2.1% reduction in his reported holdings; these trades were disclosed without a 10b5-1 designation, which can attract greater investor concern about insider confidence. SEC Form 4
Negative Sentiment: Insider Noah Goodman sold 1,347 shares on April 14 at about $90/share; that trade was also disclosed without a stated 10b5-1 plan and reduces insider ownership modestly. SEC Form 4

About Kymera Therapeutics

(Get Free Report)

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.